Projet MMM (Horizon Europe, appel à projets 2022)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

Modern medicine seeks to personalize diagnosis and treatment to the needs of individual patients. This need is heightened in particular for those individual patients where no treatments are available – and where current standard treatment development paradigms exclude to generate such. The ultimate goal of Medicine made to Measure (MMM) is to go even beyond the latest genetic medicine approaches, implementing a novel paradigm of treatment development: the field of single patient tailored antisense oligonucleotide (ASO) treatments for patients with nano-rare disease mutations. Specifically, MMM will develop core modules of a novel “out-of-the-box”, but still EMA-advised treatment development path for these patients - from omics-based theranostics, via preclinical target validation to innovative trial methodology and a pioneering ethical framework for individualised genetic therapies. MMM provides a unique opportunity for doctoral candidates to be involved in building - and to receive training - in all core modules needed for tailored ASO treatment in Europe. This new scientific field requires a new generation of open-minded, technology-fluent and applications-oriented experts. MMM will help educate future drug development and translational experts in adopting and disseminating such a cross-specialty approach. Our idea for this innovative training network is built on our personal experience and understanding of the importance of single patient tailored genetic treatments in the years to come. We propose a consortium of world-leading experts and partners that present with extended experience and relevant know-how in molecular biology, neurology, translational medicine, biochemistry, bioinformatics, philosophy, mathematics, regulatory science and engineering. Thus, MMM provides an exceptional platform to young, ambitious and talented researchers who like to engage in supporting the concept of single patient tailored treatments.

Mots clés : personalised genetic medicine, antisense oligonucleotides, severely debilitating or life threatening rare neurological diseases, single patient tailored antisense oligonucleotide treatments

Participants :
- Medicines Evaluation Board (Pays-Bas) — Partner, associated partner, Organismes publics (hors enseignement & recherche), subvention : 0.0 €
- Xnapharma gmbh (Allemagne) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Leiden University Medical Center (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 548740.8 €
- BioTalentum (Hungary) (Hongrie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 228348.0 €
- Université Eberhard Karl de Tübingen (Allemagne) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 217116.0 €
- Université d'Uppsala (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 293709.6 €
- Université technique d'Ilmenau (Allemagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- AstraZeneca (Sweden) (Suède) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Grasshopper films gbr (Allemagne) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Mhealth technologies srl (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 259437.6 €
- CeGaT (Germany) (Allemagne) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Fitt - institut fur technologietransfer an der hochschule fur technikund wirtschaft des saarlandes gemeinnutzige gmbh (Allemagne) — Partner, associated partner, Recherche, subvention : 0.0 €
- Essen University Hospital (Allemagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de Bologne (Italie) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de Cambridge (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université Louis-et-Maximilien de Munich (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 217116.0 €
- Bianogmp gmbh (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 217116.0 €
- Charles river laboratoiries den bosch bv (Pays-Bas) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Eurordis - rare diseases Europe (France) — Partner, associated partner, Autres, subvention : 0.0 €
- N=1 collaborative, inc. (Etats-Unis) — Partner, associated partner, Recherche, subvention : 0.0 €
- University Hospital Heidelberg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 217116.0 €
- Natural and Medical Sciences Institute (Allemagne) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Magyar agrar- es elettudomanyi egyetem (Hongrie) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €